Docetaxel Plus 6-month Androgen Suppression and Radiation Therapy Versus 6-month Androgen Suppression and Radiation Therapy for Patients With High Risk Localized or Locally Advanced Prostate Cancer: A Randomized Controlled Trial
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Docetaxel (Primary) ; Antiandrogens
- Indications Prostate cancer
- Focus Therapeutic Use
- 08 Jul 2021 Status changed from active, no longer recruiting to completed.
- 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology
- 28 Dec 2020 Planned End Date changed from 30 Aug 2021 to 1 Aug 2021.